Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions

In this article we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

Recent Content

Two novel mutations in the anaplastic lymphoma kinase (ALK) gene in ALK-positive lung cancer patients that confer resistance to the ALK inhibitor alecitinib, have been identified.

Researchers have identified a new strategy to approach resistance to therapies for patients with hematologic cancers—treating the malignancies upfront with a sequence of treatments that exploit the vulnerabilities of these cancer types.

The bacteria Bacillus anthracis, is responsible for the potentially deadly infection known as anthrax. While healthcare professionals and researchers alike have gone to great lengths to treat and minimize exposure to this lethal disease, others are utilizing the bacteria's intricate machinery as a way to deliver cancer drugs.

Children and young adults with Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) who have a poor prognosis may benefit from treatment with tyrosine kinase inhibitors that are already approved by the US Food and Drug Administration (FDA).

The addition of neoadjuvant carboplatin to a regimen of taxane-anthracycline chemotherapy and targeted therapy substantially increased pathological complete responses in patients with stage II/III triple-negative breast cancer (but not in patients with HER2-positive disease), according to findings of the randomized phase II GeparSixto study conducted by the German Breast Group.

As cancer treatment continues to get more targeted, the search for reliable biomarkers to identify patients most likely to benefit from this novel and expensive therapy is essential.  The driving role of the androgen receptor in prostate

A new analysis of the exome of primary bladder cancer has found a relatively frequent mutation in a gene called BAP1 (BRCA1 associated protein-1).

By clicking Accept, you agree to become a member of the UBM Medica Community.